Oculis Holding AG (NASDAQ:OCS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $38.3333.

Several research analysts recently weighed in on the stock. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. HC Wainwright cut their price target on shares of Oculis from $47.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Guggenheim cut their price target on shares of Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Finally, Stifel Nicolaus cut their price target on shares of Oculis from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, June 1st.

Oculis Stock Up 2.5%

Oculis stock opened at $10.98 on Wednesday. Oculis has a fifty-two week low of $10.52 and a fifty-two week high of $34.47. The stock has a market cap of $636.62 million, a PE ratio of -5.15 and a beta of 0.23. The firm’s 50-day simple moving average is $25.89 and its 200 day simple moving average is $24.86. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Friday, May 8th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.14). Oculis had a negative return on equity of 56.78% and a negative net margin of 8,460.67%.The firm had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.25 million. Research analysts predict that Oculis will post -2.27 EPS for the current fiscal year.

Institutional Trading of Oculis

Hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. raised its position in Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after acquiring an additional 1,000 shares during the period. Aventura Private Wealth LLC bought a new stake in shares of Oculis in the fourth quarter valued at approximately $80,000. Koshinski Asset Management Inc. bought a new stake in shares of Oculis in the first quarter valued at approximately $238,000. Millennium Management LLC bought a new stake in shares of Oculis in the fourth quarter valued at approximately $312,000. Finally, Himension Capital Singapore PTE. LTD. bought a new stake in shares of Oculis in the first quarter valued at approximately $503,000. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.